San Diego, CA – June 25, 2025 – Viking Therapeutics, a clinical-stage biopharmaceutical company, has officially launched a Phase I clinical trial for its novel therapeutic candidate, VK3019. This groundbreaking drug is designed as a dual amylin and calcitonin receptor agonist, aiming to offer a new and potentially more effective approach to weight loss management. The commencement of this trial marks a significant milestone for Viking Therapeutics, underscoring its commitment to addressing the growing global obesity epidemic with innovative pharmacological solutions.
The U.S. Food and Drug Administration (FDA) has given its approval for the investigational new drug application, paving the way for this crucial first-in-human study. The Phase I trial is a meticulously designed, randomized, double-blind, placebo-controlled, single ascending dose study. It will enroll healthy adult participants who have a body mass index (BMI) of 30 or greater, a threshold indicative of obesity. This rigorous trial design is intended to provide a comprehensive initial assessment of VK3019’s safety and how the human body processes and responds to it.
Core Objectives: Assessing Safety, Efficacy, and Pharmacological Profile
The primary objectives of this pivotal Phase I trial are multifaceted, focusing on establishing a foundational understanding of VK3019’s behavior in humans. These include:
- Tolerability Assessment: A key goal is to determine how well participants tolerate VK3019 when administered as a single subcutaneous dose. This involves monitoring for any adverse events, assessing the severity of any reported side effects, and establishing a safe dose range for future studies.
- Pharmacokinetics (PK) Evaluation: Understanding the pharmacokinetic profile of VK3019 is critical. This involves studying how the drug is absorbed into the bloodstream, distributed throughout the body, metabolized, and ultimately excreted. This data will inform dosing strategies for subsequent trials and help predict drug behavior in different patient populations.
- Safety Profiling: Comprehensive safety monitoring will be in place throughout the trial. This includes regular physical examinations, vital sign measurements, laboratory tests (blood and urine analyses), and electrocardiograms (ECGs) to detect any potential safety concerns.
Beyond these primary objectives, the trial will also incorporate exploratory assessments. These will delve deeper into the drug’s biological effects, specifically tracking pharmacodynamic changes. A key pharmacodynamic measure in this initial study will be the monitoring of body weight following the administration of a single dose. This will provide early insights into VK3019’s potential for inducing weight loss, a critical step in validating its therapeutic promise.
The investigational drug, VK3019, is engineered to act on both the amylin and calcitonin receptors. These receptors play crucial roles in regulating appetite, satiety, and energy expenditure. By simultaneously targeting both, VK3019 aims to offer a synergistic effect that could lead to more pronounced and sustained weight loss compared to therapies that target single pathways. This dual-agonist approach is a sophisticated strategy that reflects the complex biological underpinnings of obesity.
A Strategic Expansion: Building on a Robust Pipeline
The initiation of the VK3019 Phase I trial represents a strategic expansion of Viking Therapeutics’ portfolio of novel therapies. The company is actively pursuing innovative treatments designed to optimize the weight loss journey for both patients and their healthcare providers. This latest development complements Viking’s ongoing work with other promising weight management candidates.
The CEO of Viking Therapeutics, Brian Lian, expressed enthusiasm about this significant step forward. "The initiation of VK3019’s Phase I study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians," Lian stated. He further elaborated on the potential of dual-receptor agonists: "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management."
This statement highlights the potential for VK3019 to be integrated into existing or future treatment paradigms, offering flexibility and enhanced efficacy. The complexity of managing obesity, a chronic and multifactorial disease, necessitates a diverse range of therapeutic options. Lian emphasized this point: "Given the complexity of managing obesity and related metabolic conditions, broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss."
A Chronological Journey Towards Innovation
Viking Therapeutics has demonstrated a consistent trajectory of progress in its pursuit of effective obesity treatments. The development of VK3019 and its subsequent entry into Phase I trials is a culmination of extensive preclinical research and development.
- Preclinical Development: Prior to human trials, VK3019 underwent rigorous preclinical testing in laboratory and animal models. These studies were essential for characterizing the drug’s mechanism of action, assessing its safety profile, and identifying potential therapeutic effects. The positive outcomes from these preclinical investigations provided the necessary data to support the progression to human clinical trials.
- Investigational New Drug (IND) Application: Following successful preclinical studies, Viking Therapeutics submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This comprehensive submission detailed the preclinical data, manufacturing information, and the proposed clinical trial protocol for VK3019. The FDA’s acceptance of the IND application signifies that the agency has reviewed the available data and deemed it sufficient to allow for human testing.
- Phase I Trial Initiation: The formal commencement of the Phase I clinical trial, as announced today, represents the first time VK3019 will be administered to human participants. This trial is designed to evaluate the safety, tolerability, and pharmacokinetic profile of the drug in a controlled clinical setting.
Supporting Data and the Broader Context of Weight Management Therapies
The development of VK3019 is situated within a rapidly evolving landscape of weight management therapies. The success of drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which target the GLP-1 and GIP pathways, has significantly advanced the field and underscored the potential of pharmacotherapy for obesity. These drugs have demonstrated substantial weight loss and improvements in cardiometabolic risk factors.
VK3019’s dual-agonist approach, targeting amylin and calcitonin receptors, offers a complementary or alternative strategy. Amylin, a hormone co-secreted with insulin, plays a role in glucose homeostasis and satiety. Calcitonin, primarily known for its role in calcium regulation, also influences appetite and energy balance. By engaging both receptor systems, VK3019 may offer distinct advantages in weight management, potentially addressing different physiological pathways involved in appetite regulation and energy expenditure.
The exploratory assessment of body weight changes in the Phase I trial, while preliminary, will provide early signals of VK3019’s efficacy. If these initial findings are positive, they will pave the way for larger, more comprehensive clinical trials.
Official Responses and Industry Perspectives
The announcement of the VK3019 Phase I trial has been met with considerable interest from the scientific and investment communities. The CEO’s statement reflects the company’s strategic vision and optimism.
"The initiation of VK3019’s Phase I study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians," Brian Lian, CEO of Viking Therapeutics, stated. He further articulated the potential of such therapies: "Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management. Given the complexity of managing obesity and related metabolic conditions, broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss."
This perspective underscores the understanding that obesity is a complex disease requiring a multifaceted therapeutic approach. The potential for combination therapies, as suggested by Lian, is a significant area of research and development in the obesity field.
Implications for Patients and the Future of Obesity Treatment
The progression of VK3019 into human clinical trials holds significant implications for individuals struggling with obesity and related metabolic conditions. If successful, VK3019 could offer a new therapeutic option, potentially enhancing weight loss outcomes and improving overall health for a broader patient population.
Key Implications:
- Expanded Treatment Options: The development of VK3019, along with other emerging therapies, signifies a growing arsenal of tools for healthcare providers to combat obesity. This diversity in treatment options can lead to more personalized and effective management strategies.
- Potential for Combination Therapies: As highlighted by Viking Therapeutics, VK3019 could be utilized in combination with existing or future therapies. This synergistic approach may lead to greater efficacy and better long-term weight management, addressing the challenges of weight regain often seen with monotherapies.
- Addressing Unmet Needs: While current GLP-1-based therapies have shown remarkable success, not all patients respond optimally. Therapies targeting different biological pathways, such as VK3019, are crucial for addressing the needs of those who may not achieve sufficient weight loss or experience significant side effects with existing treatments.
- Advancing Scientific Understanding: Each clinical trial, including this Phase I study of VK3019, contributes to a deeper understanding of the complex biological mechanisms underlying obesity and metabolic health. This knowledge is invaluable for future drug discovery and therapeutic innovation.
Viking Therapeutics is also actively engaged in Phase III clinical trials for its other lead obesity candidate, VK2735. This drug is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist and is being investigated in obese and overweight adults, including those with type 2 diabetes, in both subcutaneous and oral formulations. The company recently announced the completion of patient enrollment in its Phase III VANQUISH-2 trial for VK2735 in March 2026, further demonstrating its commitment to advancing multiple promising therapies through the clinical development pipeline.
The journey of VK3019 from preclinical research to Phase I human trials is a testament to Viking Therapeutics’ dedication to innovation in the field of metabolic health. As the trial progresses, the scientific community and patients alike will eagerly await the results, hoping for a breakthrough that could redefine the landscape of weight loss treatment.
About the Author
